FIELD: veterinary medicine.
SUBSTANCE: group of inventions relates to a dedicated monoclonal antibody that binds to dog CD20. The group of inventions also relates to a method for treatment of lymphoma in a dog, comprising administrtion of at least one effective dose of the said monoclonal antibody; nucleic acid encoding the said monoclonal antibody.
EFFECT: effective treatment of lymphoma in dogs.
16 cl, 4 ex, 6 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS FOR THEIR USE | 2012 |
|
RU2626527C1 |
| THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS FOR THEIR USE | 2012 |
|
RU2627191C2 |
| MONOCLONAL ANTI-CD20-ANTIBODY | 2006 |
|
RU2415871C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
| PHARMACEUTICAL COMPOSITION FOR PANCREATIC CANCER TREATMENT AND/OR PREVENTION | 2012 |
|
RU2630638C2 |
